ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for samfunnsmedisin
  • Artikler, rapporter og annet (samfunnsmedisin)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for samfunnsmedisin
  • Artikler, rapporter og annet (samfunnsmedisin)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis

Permanent lenke
https://hdl.handle.net/10037/10528
DOI
https://doi.org/10.1007/s10549-016-4002-x
Thumbnail
Åpne
article.pdf (1013.Kb)
Main article (PDF)
Dato
2016-10-05
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Stub, Trine; Hervik, Jill Brook
Sammendrag
Purpose: To access frequency and severity of adverse effects (AE) of non-hormonal drugs (NHD) for hot flashes in breast cancer survivors compared to controls and analyze adverse-effect risk by reviewing published randomized trials.

Methods: Cochrane Central Register for Controlled Trials, Embase, Medline, PsycINFO and PubMed databases were searched. Trials were included where participants were survivors of breast cancer suffering from hot flashes, treatment included self-administered venlafaxine, gabapentin or clonidine, and AE were reported. AE frequency and severity were graded. A meta-analysis of ten trials with sub-group analyses was conducted.

Results: Forty-nine studies were identified, and 12 were included. A total of 1467 participants experienced 772 adverse effects, 81 % (n = 627) in the treatment group and 19 % (n = 145) in the control group. Sixty-seven percent of AE was graded as mild and 33 % as moderate. The frequency of AE for NHD was overall significant compared to placebo. Sub-group analysis indicated that AE frequency and severity increased at higher doses of venlafaxine and gabapentin compared to placebo.

Conclusion: The odds for experiencing AE was significantly higher in patients randomized to high-dose NHD than those randomized to controls, including placebo, lowdose medication and acupuncture. These therapies should be considered as a potential treatment alternative.

Beskrivelse
Published version. Source at http://dx.doi.org/10.1007/s10549-016-4002-x
Forlag
Springer
Sitering
Hervik, J. B., Stub, T.: Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors, suffering from hot flashes: A systematic review and meta-analysis. Breast Cancer Research and Treatment. 2016;160(2):223-236
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (samfunnsmedisin) [1514]

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring